NEWS HIGHLIGHTSMedia Articles Related to Guanfacine
ADHD: Once-Daily INTUNIV (Guanfacine) Extended Release Tablets Now Available In US Pharmacies
Source: ADHD News From Medical News Today [2009.11.11]
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD.
Study Findings On ADHD Treatments Presented At Psychiatric Meeting
Source: ADHD News From Medical News Today [2009.10.30]
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV™ (guanfacine) Extended Release Tablets, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, and Daytrana® (methylphenidate transdermal system) CII, at a national meeting of psychiatrists being held October 27 - November 1 in Honolulu.
New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications
Source: Hypertension News From Medical News Today [2009.11.18]
Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Kids with CKD Often Have Masked Hypertension (CME/CE)
Source: MedPage Today Nephrology [2009.11.13]
Many children with chronic kidney disease may have undetected hypertension, placing them at risk for enlarged hearts and future cardiovascular disease, a cross-sectional study showed.
Key Player Identified In Cascade That Leads To Hypertension-Related Kidney Damage
Source: Hypertension News From Medical News Today [2009.11.06]
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel constrictor and inflammatory peptide, increases the number of T cells in the kidneys, which helps recruit other immune cells, causing inflammation and destruction.
Published Studies Related to Guanfacine
A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. [2008.01]
OBJECTIVE: With this study we assessed the efficacy and safety of an extended-release formulation of guanfacine compared with placebo for the treatment of children and adolescents with attention-deficit/hyperactivity disorder... CONCLUSIONS: Guanfacine extended release met the primary and secondary efficacy end points. It was well tolerated and effective compared with placebo.
A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. [2008]
Preclinical and clinical studies demonstrate a hyperactivity of the norepinephrine system in patients with posttraumatic stress disorder (PTSD). a(2) adrenergic agonists have been shown to ameliorate symptoms of PTSD, likely because of their ability to dampen noradrenergic tone... Similar to previous findings, this small pilot study failed to show differences in the response to guanfacine versus placebo in a small sample of predominantly male combat veterans with PTSD.
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. [2007.09]
BACKGROUND: Guanfacine hydrochloride is an alpha(2a)-adrenoreceptor agonist found to be effective in the treatment of attention-deficit/hyperactivity disorder (ADHD). Because the available immediate-release formulation requires multiple daily dosing and has been associated with rebound hypertension on abrupt cessation, an extended-release (ER) formulation has been developed for study of efficacy and tolerability parameters in patients with ADHD. OBJECTIVE: This trial was primarily undertaken to determine the effect on blood pressure (BP) of abrupt cessation versus taper-down of guanfacine ER... CONCLUSION: In this small study group of healthy, young-adult volunteers, guanfacine ER at doses up to 4 mg/d was abruptly discontinued without significant increases in SBP or DBP or other tolerability parameters, including AEs, compared with taper.
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. [2007.05.15]
BACKGROUND: The signature of impaired cognition in people with schizotypal personality disorder (SPD) may be centrally related to working memory impairments. Guanfacine, an alpha2A agonist that acts post-synaptically in the prefrontal cortex (PFC), has shown potential for reducing working memory limitations in other populations. This study examined the potential of guanfacine for improving context processing, a feature of working memory, in SPD... CONCLUSIONS: SPD participants improved in their context processing toward a normal response bias, making fewer BX and more AY errors, after being treated with guanfacine.
No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. [2006.12]
CONCLUSIONS: These results do not support the use of alpha 2 agonists in veterans with chronic PTSD.
Clinical Trials Related to Guanfacine
Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia [Active, not recruiting]
Our overall aim is to determine if the administration of guanfacine in combination with
aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than
any of those medications alone in treating some of the cognitive impairment in
schizophrenia.
Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD) [Completed]
This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the
study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and
second, to explore neurobiological mechanisms of action of guanfacine.
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects [Recruiting]
This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist
guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy
elderly subjects.
Guanfacine Immediate-Release Thorough QTc Study [Recruiting]
Guanfacine to Treat Borderline Personality Disorder [Recruiting]
This study is designed to investigate whether guanfacine (Tenex) is an effective treatment
for borderline personality disorder (BPD), an illness often characterized by unstable mood
and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain,
a region associated with attention and the control of behavior. We believe that guanfacine
may improve symptoms of BPD by improving attention and aiding regulation of behavior.
|
